Business
Immutep Quarterly Activities Report Q3 FY25
Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcomaPatient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or met
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":246,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIIfOSI4irhaeByOTtn6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578","width":246,"height":103}},"lazy":false},{"type":"text","content":"Media Release","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA® in resectable soft tissue sarcoma","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Patient enrolment completed for the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA® and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLC","length":168,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong cash position of A$146.25 million, providing an expected cash reach to the end of CY2026","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":597,"olType":false},{"type":"text","content":"SYDNEY, AUSTRALIA, April 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 31 March 2025 (Q3 FY25).","length":326,"tagName":"p"},{"type":"text","content":"EFTI DEVELOPMENT PROGRAM FOR CANCER","length":35,"tagName":"p"},{"type":"text","content":"TACTI-004 – First Patient Successfully Dosed in Pivotal Phase III Trial in 1L NSCLCIn March 2025, Immutep announced the first patient in the Company’s pivotal TACTI-004 Phase III trial was successfully dosed at Calvary Mater Newcastle Hospital in Australia. TACTI-004 evaluates eftilagimod alfa...